DNTH Earnings Dianthus Therapeutics, Inc. /De/
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–23 of 23
| Q2 2026 | 2026-06-30 | -1.75 | 2026-08-04 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.85 | 2026-05-05 | 10-Q |
| FY 2025 | 2025-12-31 | -4.20 | 2026-03-09 | 10-K |
| Q3 2025 | 2025-09-30 | -2.68 | 2025-11-05 | 10-Q |
| Q2 2026 | 2025-06-30 | -1.71 | 2026-08-04 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.82 | 2026-05-05 | 10-Q |
| FY 2025 | 2024-12-31 | -2.55 | 2026-03-09 | 10-K |
| Q3 2025 | 2024-09-30 | -1.73 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.99 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.54 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -8.45 | 2025-03-11 | 10-K |
| Q3 2024 | 2023-09-30 | -17.40 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -20.84 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -8.10 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -32.57 | 2024-03-21 | 10-K |
| Q3 2023 | 2022-09-30 | -21.00 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.68 | 2023-08-03 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.39 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -1.29 | 2023-03-23 | 10-K |
| Q3 2022 | 2021-09-30 | -0.97 | 2022-11-03 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.67 | 2022-08-04 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.36 | 2022-05-16 | 10-Q |
| FY 2021 | 2020-12-31 | -1.71 | 2022-03-08 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.